Skip to content
AnalystLens

Neurocrine Biosciences 8-K Report, Executive Changes (Oct 11, 2024)

Reports
Leadership Changes
Filing Date
Filed October 11, 2024
Period End
October 11, 2024
Security
NBIX
In the record · 2016–202610-K1210-Q338-K128

NBIX filed 12 annual reports (10-K), 33 quarterly reports (10-Q) and 128 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jan ’19Jan ’19
  2. Leadership change8-K · May ’22May ’22
  3. Leadership change8-K · Sep ’26Sep ’26

Summary

Summary of the 8-K filed October 11, 2024. Cited figures are marked; the original filing is the authoritative source.

Neurocrine Biosciences, Inc. filed this Form 8-K under Item 5.02 to disclose an Amended and Restated Employment Agreement with Kyle Gano, Ph.D., entered into on October 11, 2024, in connection with a previously announced leadership transition.

Under the agreement, Dr. Gano becomes President and Chief Executive Officer effective October 11, 2024, with an annual base salary of $900,000a and an initial target annual cash incentive bonus equal to 100% of base pay earned for the applicable year. Dr. Gano will receive promotion equity grants under the 2020 Equity Incentive Plan, as amended: stock options with a target grant value of approximately $750,000 vesting in equal monthly installments over four years, restricted stock units with a target grant value of approximately $300,000 vesting in equal annual installments over four years, and performance-vesting restricted stock units with a target grant value of approximately $450,000 vesting under the terms of the March 2024 executive PRSU grants. These grants are scheduled to be made automatically two business days after the filing of the company's first Form 10-Q following the Effective Date, provided he remains employed, with share numbers set by the grant-date stock price.

The agreement also sets severance terms. Outside a change in control determination period (from a change in control through 12 months after), a termination without cause or resignation for good reason triggers 1.5 times the sum of base salary and target bonus, a pro rata actual bonus, up to 18 months of health premiums, and vesting over a 15-month period, with discretionary vesting of performance awards. Within that period, the multiple rises to 2 times, with a pro rata target bonus, up to 24 months of health premiums, and full equity vesting, with performance awards vesting at the greater of target or actual.

Death or disability triggers full equity vesting. The full agreement will be filed as an exhibit to a subsequent SEC filing.

Key Highlights

  1. Kyle Gano, Ph.D. becomes President and Chief Executive Officer of Neurocrine Biosciences effective October 11, 2024, as part of a previously announced leadership transition.
  2. Base salary set at $900,000 with an initial target annual cash incentive bonus equal to 100% of base pay earned for the applicable year.
  3. Promotion equity grants total target values of approximately $750,000 in stock options, $300,000 in RSUs, and $450,000 in performance-vesting RSUs.
  4. Promotion equity grants are automatically made two business days after the first Form 10-Q filed following the Effective Date, contingent on continued employment.
  5. Non-change-in-control severance: 1.5x the sum of base salary and target bonus, pro rata actual bonus, up to 18 months of health premiums, and 15 months of accelerated time-vesting, subject to a release of claims.
  6. Change-in-control severance (12 months after a change in control): 2x the sum of base salary and target bonus, pro rata target bonus, up to 24 months of health premiums, and full equity vesting.
  7. Death or disability triggers full acceleration of outstanding equity awards, with performance awards vesting at the greater of target or actual performance.

Frequently Asked Questions

  1. When does Kyle Gano become CEO and what is his base compensation?

    Dr. Gano becomes President and Chief Executive Officer effective October 11, 2024, with an annual base salary of $900,000 and an initial target annual cash incentive bonus equal to 100% of his base pay earned for the applicable year.

  2. What equity awards will Dr. Gano receive in connection with his promotion?

    He will receive stock options with a target grant value of approximately $750,000 vesting monthly over four years, RSUs with a target grant value of approximately $300,000 vesting annually over four years, and performance-vesting RSUs with a target grant value of approximately $450,000 vesting under the terms of the March 2024 executive PRSU grants. The share numbers will be set by the stock price on the grant date.

  3. When will the promotion equity grants be made?

    The grants will be made automatically on the date two business days after the filing of the company's first Form 10-Q following the October 11, 2024 Effective Date, provided Dr. Gano remains employed on that date.

  4. What severance protections does Dr. Gano have?

    Outside the change-in-control determination period, a termination without cause or resignation for good reason (excluding death or disability) provides 1.5x base salary plus target bonus, a pro rata actual bonus, up to 18 months of health premiums, and accelerated vesting for awards scheduled to vest over the following 15 months, all subject to a release of claims. Within 12 months after a change in control, the cash multiple is 2x, with a pro rata target bonus, up to 24 months of health premiums, and full equity vesting.

  5. Where can investors find the full terms of the Employment Agreement?

    The filing states that the full Employment Agreement will be filed as an exhibit to a subsequent filing with the Securities and Exchange Commission, and that the description in this filing is qualified in its entirety by that document.